ELRIG Drug Discovery 2019

//ELRIG Drug Discovery 2019
Loading Events
This event has passed.

Metrion Biosciences will be attending ELRIG Drug Discovery 2019 to be held at the ACC Arena, Liverpool on 5th and 6th November 2019.

Dr Marc Rogers, Chief Scientific Officer, will be presenting an ion channel drug discovery focused talk at 12.10-12.30 during the British Pharmacology Society track ‘Targeting Ion Channels for Drug Discovery” which takes place on Tuesday 5th November 2019.

Metrion’s Business Manager, Dr John Ridley will be at Metrion’s exhibition booth, G16, in the exhibits hall for the duration of the meeting and will be on hand to discuss Metrion’s range of ion channel drug discovery services.

Metrion’s Poster (#112) which focuses on our cardiac and neuroscience capabilities will be displayed throughout the meeting.

Please email info@metrionbiosciences.com if you would like to arrange a meeting with Metrion’s representatives.

Metrion Biosciences is a UK-based Contract Research Organization (CRO) located within the Cambridge bio cluster, one of Europe’s largest bioscience research hubs. Our state of the art laboratories at Granta Park house high quality facilities for native and engineered cell line and induced pluripotent stem cell culture, a comprehensive suite of automated patch clamp platforms, multiple manual patch clamp rigs, fluorescence-based screening capability and laboratory data management and reporting systems. Our company is focused upon delivering a range of high quality ion channel drug discovery services. We provide highly skilled electrophysiology screening services to support client medicinal chemistry optimisation programmes, CiPA compliant cardiac safety profiling assays, neuroscience assays and translational assays. We combine in depth target class knowledge and high quality screening assays with highly experienced and collaborative drug discovery managers to keep your research focused upon meeting both objectives and timelines. Our team has successfully delivered many projects on behalf of our clients from once off screening projects to fully integrated drug discovery programmes delivering clinical candidates.